Previous Article | Next Article 
Clinical and Diagnostic Laboratory Immunology, November 1998, p. 773-779, Vol. 5, No. 6
1071-412X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Antigenic Structure of the Nucleocapsid Protein of
Porcine Reproductive and Respiratory Syndrome Virus
Sarah K.
Wootton,1
Eric A.
Nelson,2 and
Dongwan
Yoo1,*
Department of Pathobiology, Ontario
Veterinary College, University of Guelph, Guelph, Ontario N1G 2W1,
Canada,1 and
Department of Veterinary
Science, South Dakota State University, Brookings, South Dakota
570072
Received 15 May 1998/Returned for modification 7 August
1998/Accepted 21 August 1998
 |
ABSTRACT |
A collection of 12 monoclonal antibodies (MAbs) raised against
porcine reproductive and respiratory syndrome (PRRS) virus was used to
study the antigenic structure of the virus nucleocapsid protein (N).
The full-length N gene, encoded by open reading frame 7, was cloned
from the Canadian PRRS virus, PA-8. Deletions were introduced into the
N gene to produce a series of nine overlapping protein fragments
ranging in length from 25 to 112 amino acids. The individual truncated
genes were cloned as glutathione S-transferase fusions into
a eukaryotic expression vector downstream of the T7 RNA polymerase
promoter. HeLa cells infected with recombinant vaccinia virus
expressing T7 RNA polymerase were transfected with plasmid DNA encoding
the N protein fragments, and the antigenicity of the synthesized
proteins was analyzed by immunoprecipitation. Based on the
immunoreactivities of the N protein deletion mutants with the panel of
N-specific MAbs, five domains of antigenic importance were identified.
MAbs SDOW17, SR30, and 5H2.3B12.1C9 each identified independent domains
defined by amino acids 30 to 52, 69 to 123, and 37 to 52, respectively.
Seven of the MAbs tested specifically recognized the local protein
conformation formed in part by the amino acid residues 52 to 69. Furthermore, deletion of 11 amino acids from the carboxy terminus of
the nucleocapsid protein disrupted the epitope configuration recognized
by all of the conformation-dependent MAbs, suggesting that the
carboxy-terminal region plays an important role in maintaining local
protein conformation.
 |
INTRODUCTION |
Porcine reproductive and respiratory
syndrome (PRRS) is presently one of the most important infectious
diseases of swine. The disease, which first appeared in North America
in 1987, is characterized by severe reproductive failure and
respiratory distress (1). The specific viral etiology of
PRRS was originally established in The Netherlands (26) and
was given the name Lelystad virus. In 1992, the first North American
isolate responsible for PRRS was identified (3) and
designated VR-2332. Although North American and European isolates of
PRRS virus have morphological and structural similarities, they display
significant molecular and antigenic variation, which suggests that they
represent two distinct serotypes (17, 25).
PRRS virus consists of a plus-sense polyadenylated RNA genome (15 kb)
surrounded by a cubical nucleocapsid core and a lipoprotein envelope.
Nucleotide sequence analysis of the entire Leylstad virus genome
(14) and the bulk of the VR-2332 genome (4) identified eight overlapping open reading frames (ORFs). ORFs 1a and
1b, which are expressed from genomic RNA, occupy more than two-thirds
of the genome and encode the viral RNA polymerase. ORFs 2 to 7, located
downstream of ORF 1b, encode the structural proteins. ORFs 2 through 5 code for membrane glycoproteins, ORF 6 encodes a nonglycosylated
membrane protein, and ORF 7 encodes a highly basic nucleocapsid (N)
protein. These genes are expressed from a 3'-coterminal nested set of
functionally monocistronic subgenomic mRNAs (19). Based on
genome organization, replication strategy, and propensity for infecting
macrophages, PRRS virus has been classified in the genus
Arterivirus in the newly proposed family
Arteriviridae (2). Other members of this family
include lactate dehydrogenase-elevating virus, equine arteritis virus, and simian hemorrhagic fever virus (SHFV).
The products of ORFs 5, 6, and 7 constitute the major structural viral
proteins (13). These proteins elicit discrete populations of
functional antibodies (Abs) at various times during infection (15), with the N protein evoking the greatest immune
response (20). Comparative analysis of the predicted N
protein amino acid sequence indicates that this protein is well
conserved among PRRS virus isolates within a given genotype, often
displaying between 96 and 100% amino acid identity (11,
12). Furthermore, the antigenic character of the N protein
appears to be largely conserved. This was illustrated by the results of
a recent study in which 89% of 300 North American PRRS virus isolates
tested reacted positively with a panel of 11 well-characterized
N-specific monoclonal Abs (MAbs) (18). By virtue of its
antigenic properties and sequence homology, the N protein has been used
for detection of PRRS virus-specific antibodies in swine sera as well
as for production of diagnostic reagents (24). Moreover,
N-specific MAbs have been utilized to differentiate North American and
European isolates of PRRS virus (17). Therefore, information
regarding the antigenic properties of the N protein will facilitate
classification of diagnostic MAbs according to their epitope specificities.
In the present study, a series of MAbs raised against several PRRS
virus isolates was used to study the antigenic structure of the
nucleocapsid protein. DNA fragments constituting discrete segments of
the N protein were derived from the N coding region (ORF 7) of the PA-8
PRRS virus. The immunoreactivities of the N-specific MAbs with each of
the fusion protein fragments produced in mammalian cells was analyzed
by radioimmunoprecipitation (RIP) and sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). The amino acid
sequences responsible for generating epitopes recognized by the MAbs in
question were mapped to five independent regions of the N protein.
 |
MATERIALS AND METHODS |
Cells, viruses, and antibodies.
HeLa cells were maintained
at 37°C and 5% CO2 in Dulbecco's modified Eagle's
medium supplemented with 10% heat-inactivated fetal bovine serum
(CanSera; Rexdale, Ontario, Canada). MARC-145 cells were similarly
maintained in Dulbecco's modified Eagle's medium supplemented with
4% heat-inactivated fetal bovine serum (10). Recombinant
vaccinia virus, vTF7-3, encoding T7 RNA polymerase was previously
constructed by Fuerst et al. (7). To prepare vTF7-3 virus
stock, HeLa cells were infected at a multiplicity of infection (MOI) of
0.1 PFU/cell. When cytopathic effects were evident, approximately
48 h postinfection, cells and media were harvested and centrifuged
at 500 × g for 10 min. The cell pellet was subjected
to one cycle of freeze-thaw to release virus particles. Cellular debris
was removed by centrifugation at 500 × g for 10 min,
and the clarified supernatant was used as crude virus stock. To prepare
the PRRS virus strain PA-8 (kindly provided by J. Cho, Animal
Disease Research Institute, Lethbridge, Alberta, Canada), MARC-145
cells were infected at an MOI of 5 PFU/cell. At 2 days postinfection,
cells and supernatant were harvested and collected by centrifugation
for 10 min at 500 × g. The clarified supernatant was
used as crude virus stock. Rabbit anti-glutathione
S-transferase (GST) polyclonal Ab (immunoglobulin G [IgG]
fraction) (Sigma, St. Louis, Mo.) was used in immunoprecipitation
experiments to identify expression of GST fusion proteins. A porcine
hyperimmune serum raised against PRRS virus was used as a positive
control to examine the antigenicity of N protein deletion mutants. A
collection of 12 N-specific MAbs was used for immunoprecipitation of
both the full-length and truncated N protein fragments. The strains of
PRRS virus utilized in the production of the N-specific MAbs, as well
as relevant references, are listed in Table
1.
RNA purification and cDNA cloning of ORF 7.
Culture
supernatant was harvested from virus-infected cells 2 days
postinfection, and cell debris was clarified. Virus was pelleted
through a 30% sucrose cushion by ultracentrifugation using an SW28
rotor at 25,000 rpm for 2 h. The virus pellet was resuspended in
Tris-EDTA (TE) buffer, and viral genomic RNA was prepared by phenol
extraction. The extracted RNA was used for cloning of the N gene. A
pair of forward (5'-CGGATC CCCTTGTCAAATATGCCAA-3') and
reverse (5'-AGAATGCCAGCCCATCA-3') primers was fashioned for N gene amplification using Vent DNA polymerase (New England Biolabs, Mississauga, Ontario, Canada). The PCR product was cloned directly into
the SmaI site of pGEM3zf(+) (Promega, Madison, Wis.) in the opposite orientation to the lacZ gene, allowing the
convenient retrieval of the N gene through BamHI digestion.
The resulting plasmid, named pGEM3zf-ORF7, represents the parental
plasmid from which the N gene derivatives were constructed. The gene
was sequenced in both directions by chain termination methods using an
ABI automated sequencer.
Construction of recombinant plasmid expression vectors.
Fragments of the N gene were cloned in frame, downstream of the T7
promoter, into the mammalian expression vector pCITE-2a (Novagen,
Madison, Wis.). Recombinant plasmids were constructed and used to
transform the Escherichia coli strain JM105 following the
methods of Sambrook et al. (23). Strategies for the
construction of the N protein deletion mutants are illustrated in Fig.
1. The carboxy-terminal deletion mutants
C-11, C-50, C-86, and C-98 were generated by digestion of pGEM3zf-ORF7
with restriction enzymes HgaI, AvaII,
MfeI, and PflMI, respectively. For C-11, C-50,
and C-86, the 5' overhang was filled in with the Klenow fragment of DNA
polymerase I, and for blunting of the 3' overhang present in C-98, T4
DNA polymerase was used. Gel-purified fragments were digested with
BamHI and subcloned into pGEX-3X (Pharmacia, Uppsala, Sweden) at the BamHI-SmaI site. To construct the
C-66 deletion mutant, the full-length N gene was first cloned into the
BamHI site of pGEX-3X. This construct was subsequently
digested with BfaI, blunted with the Klenow fragment of DNA
polymerase I, and redigested with BamHI. The
BamHI-BfaI fragment was gel purified and
subcloned back into the original pGEX-3X plasmid. The carboxy-terminal deletion mutants (C-11, C-50, C-66, C-86, and C-98) were amplified from
pGEX-3X as GST fusion proteins by using the forward primer 5'-ATTTCCATGGTCATGTCCCCTATACTAGGTT-3' and the reverse primer
5'-ATTACCATGGAACGCGCGAGGCAG-3'. PCR amplifications were
carried out with 20 ng of template DNA, 40 pmol of each primer, and 2 U
of Vent DNA polymerase. The samples were subjected to 30 cycles of
amplification under the following conditions: denaturation at 94°C
for 30 s, primer annealing at 55°C for 1 min, primer extension
at 72°C for 2 min, and final extension at 72°C for 5 min. The PCR
products were digested with NcoI and subcloned into
pCITE-2a. For the amino-terminal deletion mutants, truncated gene
fragments were cloned directly into pCITE2a-GST. To construct the
plasmid pCITE2a-GST, the GST coding sequence, obtained by PCR
amplification using the forward primer
5'-ATTTCCATGGTCATGTCCCCTATACTAGGTT-3' and the reverse primer
5'-ATTACCATGAATTCCCGGGGA-3', was digested with
NcoI and subcloned into pCITE-2a. Plasmid pGEM3zf-ORF7 was used as template DNA for the PCR amplification of the N-18, N-30, N-52,
and N-69 gene fragments. Individual fragments were amplified by using
the following forward primers:
5'-CGTAGATCTGTCAATCAGCTGTGCCAGATG-3' for N-18,
5'-GGCAGATCTATCGTTCAGCAAAACCAGTCC-3' for N-30,
5'-CCGGCAGATCTCCCCATTTTCTTCTAGCGACT-3' for N-52, and
5'-CGGAGATCTAGTGAGCGGCAATTGTGTCTG-3' for N-69 (in combination with the reverse primer
5'-GAATACTCAAGCTTGCATGCCTG-3'). The PCR products were
digested with restriction enzymes BglII and
PstI and subcloned into pCITE2a-GST.

View larger version (26K):
[in this window]
[in a new window]
|
FIG. 1.
Schematic presentation of the N protein deletion
mutants. The deletions and truncations of the N protein were
constructed as described in Materials and Methods. Locations of the
mutant proteins relative to the N protein are indicated by positions of
amino acids. Shaded areas represent the GST coding sequence, and the
black areas represent the translation termination.
|
|
Protein expression and radiolabelling.
Plasmid DNA was
prepared using plasmid purification columns (Qiagen Inc., Santa
Clarita, Calif.) according to the manufacturer's recommended
procedures. HeLa cells grown to 90% confluence in 100-mm-diameter
dishes were infected at an MOI of 5 to 10 PFU/cell with vaccinia virus
vTF7-3 and allowed to adsorb for 1 h at 37°C with occasional
rocking. Five milliliters of fresh medium containing 10% fetal calf
serum was added, and incubation continued for 1 h at 37°C. The
plasmid DNA-LipofectACE (Gibco BRL, Burlington, Ontario, Canada)
solutions were incubated in OPTI-MEM serum-reduced medium (Gibco BRL)
at room temperature for 45 min prior to transfection. The inoculum was
removed, and the cells were transfected for approximately 8 h with
10 µg of plasmid DNA and 40 µl of LipofectACE in 6.5 ml of
OPTI-MEM. The supernatant was removed at 10 h postinfection, and
the cells were labelled for 16 h with Easy Tag EXPRESS protein labelling mix (50 µCi/ml) consisting of
[35S]methionine and [35S]cysteine (specific
activity, 407 MBq/ml; New England Nuclear, Boston, Mass.) in
methionine-free Eagle's minimal essential media (Sigma) supplemented
with 2% fetal calf serum. The cells were harvested, rinsed with cold
phosphate-buffered saline, and resuspended in 600 µl of lysis buffer
(0.1% Triton X-100 and 10 mM Tris-HCl, pH 7.4). After incubation for
10 min on ice, cell lysates were centrifuged at 14,000 rpm in an
Eppendorf microcentrifuge for 10 min. The supernatant containing the
cytoplasmic fraction was collected for immunoprecipitation experiments.
Immunoprecipitation and SDS-PAGE analysis.
Aliquots (20 µl) of labelled cell lysates were adjusted with RIPA buffer (1%
Triton X-100, 1% sodium deoxycholate, 150 mM NaCl, 50 mM Tris-HCl [pH
7.4], 10 mM EDTA, 0.1% SDS) to a final volume of 100 µl and
incubated for 2 h at room temperature with 1 µl of MAb or
polyclonal Ab. The immune complexes were adsorbed to 10 mg of protein
A-Sepharose CL-4B beads (Pharmacia) for 16 h at 4°C in 800 µl
of RIPA buffer containing 0.3% SDS. The precipitates collected by
centrifugation at 6,000 rpm for 2 min were washed two times with RIPA
buffer and once with wash buffer (50 mM Tris-HCl [pH 7.4], 150 mM
NaCl). Pellets were resuspended in 20 µl of SDS sample buffer (10 mM
Tris-HCl [pH 6.8], 25% glycerol, 10% SDS, 10%
-mercaptoethanol,
and 0.12% [wt/vol] bromophenol blue) and heated for 5 min at 95°C.
After centrifugation at 10,000 rpm for 5 min, the clarified samples
were analyzed by SDS-12% PAGE and visualized by autoradiography.
Nucleotide sequence accession number.
The sequence reported
in this work has been deposited to the GenBank database under accession
no. AF066068.
 |
RESULTS |
MAb reactivities with N protein of PA-8.
Panels of MAbs
specific for the N protein have been developed by using various
PRRS isolates (5a, 13). With the exception of MAb
5H2.3B12.1C9, which was derived from immunization with formalin-fixed PRRS virus, these MAbs were all produced by immunizing with viable virus. Characteristics of those MAbs, including virus isolates used in immunization, immunoglobulin isotype, Western blot,
and RIP reactivities, are summarized in Table 1. RIP was used to
determine the specificity of all the MAbs with the N protein, whereas
5H2.3B12.1C9 was tested by Western blotting. The former MAbs reacted
negatively on Western blots, suggesting that they were specific for
discontinuous conformational epitopes on the N protein. To examine the
reactivity of those MAbs to the N protein of the PA-8 isolate,
immunoprecipitations were performed with lysates from PA-8
virus-infected cells with each of the 12 MAbs on the panel (Fig.
2A). Each of the other MAbs specifically
precipitated a protein of 15 kDa, while MAbs NS99 (lane 6) and CF163
(lane 10) did not recognize the PA-8 N protein by immunoprecipitation. No specific proteins were detected in the uninfected cells with a
mixture of all 12 MAbs (lane 2).

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 2.
(A) Specificity of the MAbs for the N protein of PA-8
virus. MARC-145 cells were infected with the PA-8 strain of PRRS virus
at an MOI of 5 PFU/cell. Virus-infected cells were labelled with
[35S]methionine at 50 µCi/ml, and cell extracts were
prepared 48 h postinfection. Immunoprecipitation was performed
with each of the 12 N-specific MAbs. Immune complexes were collected
with protein A-Sepharose and resolved by SDS-12% PAGE as described in
Materials and Methods. Uninfected cell lysate precipitated with a
mixture of all 12 MAbs on the panel was used as a negative control
(lane 2). The band migrating at 15 kDa representing the PA-8 N protein
is marked with an arrowhead. (B) Specificity of the MAbs toward the
recombinant GST-N fusion protein. HeLa cells infected with vaccinia
virus expressing T7 RNA polymerase were transfected with plasmid DNA
encoding the GST-N fusion protein under the control of the T7 promoter.
Radiolabelled cell lysates were collected and immunoprecipitated with
individual MAbs. The protein band (lanes 2 to 13) migrating at a
molecular mass of 41 kDa represents the GST-N fusion protein. MW,
molecular mass markers.
|
|
In order to study the antigenic structure required for those MAbs, the
complete coding sequence for the N protein of PA-8
virus was cloned and
sequenced (GenBank accession no.
AF066068).
The cloned N gene was able
to encode a polypeptide of 123 amino
acids. The predicted PA-8 protein
sequence was compared to those
of six isolates of PRRS virus from which
the N-specific MAbs used
in our mapping studies were derived (Table
1).
Sequence homology
ranged from 94.3 to 98.4% with respect to the North
American strains
and only 55% for the European strain. The VR-2332 N
protein showed
the highest degree of homology to that of PA-8, with
98.4% sequence
identity and substitutions at positions 31 (Val to Ala)
and 56
(Leu to Pro). These substitutions were found among all of the
isolates compared. Isolate MN-1b showed the greatest variability,
with
additional substitutions at positions 9 (Thr to Gln), 10
and 11 (Glu to
Arg), and 89 and 91 (Thr to Ile), resulting in
an overall identity of
94.3% (data not
shown).
We attempted to express the N gene in mammalian cells by the vaccinia
T7 expression system. The N coding sequence was first
cloned into the
pGEX-3X expression vector in frame with the GST
coding sequence. The
coding sequence for GST-N fusion protein
was subsequently inserted into
the mammalian expression vector
pCITE-2a downstream of the T7 RNA
polymerase promoter. A stretch
of spacer sequence of 30 amino acids was
inserted to separate
the N protein sequence from the GST sequence to
reduce potential
deleterious interactions which might occur during the
formation
of the epitopes. Expression of the N protein was confirmed by
immunoprecipitation using anti-GST antibody (data not shown).
Subsequently, immunoreactivities of the recombinant N protein
with
individual MAbs were examined. Similar to the results obtained
from
immunoprecipitation studies with PA-8-infected cell lysates,
the 41-kDa
GST-N fusion protein was recognized by all the MAbs
examined except
NS99 and CF163 (Fig.
2B, lanes 5 and 9, respectively).
Collectively,
our data show that 10 of the 12 MAbs specifically
recognize the
authentic N protein of the PA-8 isolate of PRRS
virus in addition to
the recombinant GST-N protein expressed in
cells. Due to lack of
reactivity with the PA-8 N protein, MAbs
NS99 and CF163 were eliminated
from subsequent
experiments.
Expression of GST-coupled N protein deletions in HeLa cells.
For our mapping studies, eight deletions and truncations were
constructed to represent overlapping fragments of the N protein ranging
from 25 to 112 amino acids (Fig. 1). These mutants were created by
deleting sequences progressively from either the 5' or 3' terminus of
the N coding sequence. Since our mutant constructs represent small
fragments of the N protein, it was necessary to fuse the constructs
with GST protein to facilitate visualization of the precipitated
proteins. HeLa cells, infected with recombinant vaccinia virus vTF7-3,
were transfected with plasmids encoding the deletion mutants. The
transfected cells were radiolabelled and subjected to
immunoprecipitation with anti-GST antibody. The resulting proteins
expressed in HeLa cells are shown in Fig.
3. A band migrating in agreement with the
expected molecular weight for each deletion mutant was identified
(lanes 5 to 13). Expression of the deletion mutants synthesized as GST
fusion proteins was also confirmed by reactivity with hyperimmune
antisera from swine immunized with PRRS virus (data not shown). Results
from these experiments indicated that the N deletion proteins were
synthesized as fusion proteins at sufficient levels with which to
examine the N-specific MAb reactivities.

View larger version (42K):
[in this window]
[in a new window]
|
FIG. 3.
Expression of the GST-N fusion constructs
immunoprecipitated with anti-GST antibody. HeLa cells infected with
vaccinia virus expressing T7 RNA polymerase (vTF7-3) were transfected
with plasmid DNA. Cells labelled with [35S]methionine
were collected 26 h postinfection, immunoprecipitated with
anti-GST antibody, and resolved by SDS-12% PAGE. Lane 1, molecular
mass markers (MW); lane 2, uninfected and untransfected cells; lane 3, vTF7-3-infected, untransfected cells; lane 4, vTF7-3-infected, control
plasmid DNA (pCITE2a)-transfected cells; lanes 5 to 13, lysates from
cells expressing each of the N fusion proteins.
|
|
Immunoreactivity of the N-specific MAbs with N protein
fragments.
To localize the antigenically important domains present
on the N protein of PRRS virus, the reactivities of the deletion
mutants were examined with a collection of 10 N-specific MAbs. MAb
SDOW17 reacted with the deletion mutant N-18, which migrated at the
molecular mass of 40 kDa (Fig. 4A, lane
11), but failed to recognize either N-52 and N-69 (lanes 12 and 13), or
any of the carboxy-terminal deletion mutants (lanes 6 to 10). The MAb
EP147 reacted with both N-18 and N-52 (Fig. 4B, lanes 11 and 12), but
failed to precipitate the N-69 deletion mutant (lane 13) or any of the
carboxy-terminal truncation mutants (lanes 6 to 10). MAbs VO17, MR40,
JP25, 1D2, 2G7, and 7C10 reacted similarly to EP147 in our
immunoprecipitation assays (data not shown). The deletion mutant N-69
is composed of amino acids 69 to 123; therefore, it is conceivable that
the region pertaining to amino acids 52 to 69 constitutes an
antigenically important domain for this group of MAbs. The MAb SR30
reacted with all three amino-terminal deletion mutants
N-18, N-52, and N-69 (Fig. 4C, lanes 11 to 13)
but failed to recognize any of the
carboxy-terminal deletion mutants (lanes 6 to 10). The binding pattern
observed for MAb SR30 suggests that the epitope it recognizes lies
within the carboxy-terminal region of the N protein, more specifically
between amino acids 69 and 123. In contrast to other MAbs, 5H2.3B12.1C9
recognized the carboxy-terminal deletion mutants C-11, C-50, and C-66
(Fig. 4D, lanes 6 to 8) in addition to the N-18 deletion mutant (Fig.
4D, lane 11).

View larger version (46K):
[in this window]
[in a new window]
|
FIG. 4.
Immunoprecipitation of the GST-N protein deletion
mutants with individual MAbs. HeLa cells were infected with vTF7-3 and
transfected with plasmids encoding the N protein deletion mutants.
Cells were radiolabelled with [35S]methionine (50 µCi/ml) for 16 h. Cell lysates containing the cytoplasmic
fraction were immunoprecipitated with each of the N-specific MAbs, and
the immune complexes were resolved by SDS-12% PAGE followed by
autoradiography. (A) Immunoprecipitation with MAb SDOW17; (B)
immunoprecipitation with MAb EP147 (representative also of the results
observed for MAbs VO17, MR40, JP25, 1D2, 2G7, and 7C10); (C)
immunoprecipitation with MAb SR30; (D) immunoprecipitation with MAb
5H2.3B12.1C9. Lane 1, molecular mass markers (MW); lane 2, uninfected,
untransfected HeLa cells; lane 3, vTF7-3-infected, untransfected cells;
lane 4, vTF7-3-infected, control plasmid DNA (pCITE2a)-transfected
cells; lanes 5 to 13, lysates of cells expressing each of the N protein
mutants.
|
|
 |
DISCUSSION |
Diagnosis of PRRS virus infection on the basis of clinical signs
is generally considered unreliable because symptoms often vary among
herds. Clinical diagnosis is further complicated in instances when
secondary infections produce PRRS-like symptoms. Consequently,
serological techniques including enzyme-linked immunosorbent assay
(ELISA), indirect immunofluorescence assay, and immunoperoxidase monolayer assay are routinely used in the diagnosis of PRRS virus infection. Many of these procedures rely on the highly immunogenic nature of the PRRS virus N protein, both for antibody production and
antibody detection. The following examples illustrate this point. A
highly specific indirect ELISA utilizing baculovirus-expressed N
protein as the antigen was recently developed for detecting antibodies
against PRRS virus in swine sera (5). This technique proved
to be considerably more specific than conventional ELISAs using
whole-virus antigen and less expensive and time-consuming by virtue of
its use of a single recombinant protein rather than infectious virus.
MAbs derived from PRRS virus, which are most often specific for the
15-kDa N protein, can be conjugated to fluorescein isothiocyanate to
allow detection of PRRS virus in swine tissue (24).
Furthermore, N-specific MAbs can be used for differential diagnosis of
PRRS virus infection (9). MAbs capable of distinguishing
between field and vaccine strains of PRRS virus are of particular
importance due to the fact that an attenuated live PRRS virus vaccine
is now widely administered. Moreover, multiple viral strains exist
within the swine population, and these do not frequently cross-react
serologically. Thus, knowledge about the location of epitopes on the N
protein as well as serological classification of N-specific MAbs will
serve to enhance the specificity of many serology-based diagnostic tests.
The expression of subgenomic fragments in eukaryotic cells is
frequently used to localize antigenic domains on proteins (21, 27). This approach to epitope mapping offers an advantage over other methods involving oligopeptides and/or E. coli-produced protein fragments, because viral proteins expressed
in eukaryotic cells will undergo the necessary posttranslational
modifications to ensure proper conformation. Conversely, proteins
expressed in bacteria do not possess any posttranslational
modifications; therefore, such an approach may fail to give clear
results when complex antigenic structures are involved. Previously,
PRRS virus N protein mapping studies were performed with E. coli-expressed protein fragments (22). A linear epitope
was identified between amino acids 50 and 66; however, neither this nor
any of the other E. coli-expressed N protein fragments
proved efficacious for diagnostic purposes. This can be attributed to
the fact that the majority of N-specific MAbs produced during infection
are conformation-dependent (6, 18). Consequently, for our
mapping studies we produced the N protein deletion mutants in mammalian
cells by the T7-based vaccinia virus expression system so as to
approximate native conformation.
The purpose of this study was to elucidate the structural requirements
for Ab binding by using a collection of 12 MAbs with a total of nine
different N protein constructs expressed in mammalian cells.
Immunoreactivities of the MAbs with the individual mutants are
summarized in Table 2, and the domains of
antigenic importance identified in our study are depicted in Fig.
5. In accordance with the experimental
results, MAbs were divided into four different groups, each specifying
a unique region of antigenic importance on the N protein. Domain I,
which was identified by MAb SDOW17 (group 1), was localized to the
amino-terminal region between amino acids 18 and 52 (Fig. 4A). During
the preparation of this manuscript, an additional deletion mutant,
N-30, was constructed. All the MAbs tested reacted with the N-30
product in immunoprecipitation assays (data not shown). The N-30
deletion mutant comprises amino acids 30 to 123, and N-52 comprises
amino acids 52 to 123, indicating that a region of antigenic importance
is actually located between amino acids 30 and 52 (domain I). All of
the other conformation-dependent MAbs retained binding activity upon
removal of 52 amino acids from the amino terminus (Table 2), which
suggests that this region recognized by SDOW17 contains a
relatively unique epitope. The specificity exhibited exclusively
by SDOW17 for domain I was not unexpected. It has been demonstrated
that SDOW17 is the only MAb capable of recognizing an epitope common to
almost all European and North American isolates of PRRS virus.
Consequently, SDOW17 represents a valuable diagnostic reagent. Nelson
et al. (16) identified an amino acid present on nearly all
field isolates of PRRS virus but absent from the Prime Pac PRRS vaccine
strain. By successive passages, the Prime Pac PRRS vaccine strain
acquired a mutation at position 61 that resulted in a change from
aspartic acid to tyrosine. A mutation of this nature is predicted to
disrupt
-helix conformation. This amino acid difference impaired
SDOW17 recognition of the vaccine strain. Given the fact that SDOW17 recognizes a conformational epitope common to both European and North
American genotypes, this epitope is likely to be localized within a
highly conserved region of the N protein. Moreover, sequence analysis
revealed that although there were amino acid changes scattered
throughout the N protein, a central region of well-conserved amino
acids existed between residues 47 and 100 (22). Secondary structure prediction using the method of Garnier et al. (8) suggests that this region forms a helical conformation; therefore, it
is possible that SDOW17 recognizes this highly conserved hydrophilic loop structure and that removal of 52 amino acids, but not 30 amino
acids, alters the local conformation such that SDOW17 is no longer able
to recognize the N protein. Similarly, the change from aspartic acid to
tyrosine, which is predicted to disrupt
-helix formation, may
influence overall conformation, explaining why the vaccine strain is
unrecognizable by SDOW17.

View larger version (12K):
[in this window]
[in a new window]
|
FIG. 5.
Illustration of the five antigenically important domains
localized on the N protein. The shaded areas flanked by amino acid
positions represent domains localized by the mapping studies.
|
|
Domain III, defined by amino acids 52 to 69, lies within a
well-conserved region of the N protein. This stretch of amino acids appears to be part of an immunodominant epitope, as 70% of the MAbs on
the panel recognized local protein conformation present in the N-52 but
not in the N-69 deletion mutant (Table 2), which suggests good
immunogenicity for this region. These results are corroborated by a
previous report which suggests that a well-conserved linear epitope is
located between amino acids 50 and 66 (22). Hydropathic
profile indicates that amino acids 40 to 60 are present in a
hydrophilic region of the N protein, demonstrating high solvent accessibility. It is therefore likely that the majority of MAbs recognize this portion of the protein because of its conspicuous location on the outer capsid surface.
Domain IV, which extends from amino acids 69 to 123, was defined by the
specific binding activity of MAb SR30 with deletion mutants N-18, N-52,
and N-69 (Fig. 4C). Deletion of the amino terminus does not appear to
affect the local protein conformation forming the SR30 specific
epitope. In a survey of over 300 North American PRRS virus isolates,
the MAb SR30 reacted with 100% of the field isolates tested,
whereas SDOW17 reacted with 99.4% of the isolates
(17). This suggests that like SDOW17, SR30 recognizes a
highly conserved epitope on the N protein and therefore constitutes a
valuable diagnostic tool.
MAb 5H2.3B12.1C9 was able to recognize the carboxy-terminal deletion
mutants C-11, C-50, and C-66 (Fig. 4D). It was possible to delete up to
66 amino acids from the C terminus without the C-66 mutant losing the
ability to be bound by 5H2.3B12.1C9. However, deletion of more than 30 amino acids from the N terminus disrupted the MAb binding (data not
shown). Therefore, the epitope specific for this MAb should be located
between amino acids 37 and 57 (domain II). The difference observed
between 5H2.3B12.1C9 and other MAbs may be due to the nature of the
antigen used for immunization. Unlike the other MAbs,
formalin-inactivated PRRS virus was used in the production of
5H2.3B12.1C9. Treatment with formalin, a protein cross-linking agent,
promotes conformational changes or denaturation of the antigen;
therefore, MAbs made in this fashion are likely to be specific for
linear as opposed to conformational epitopes. Thus, it is conceivable
that, because 5H2.3B12.1C9 reacted positively in Western blot
experiments (Table 1), domain II constitutes a linear epitope.
To facilitate our mapping studies, reactivities of carboxy-terminal
deletion mutants were also examined with the panel of N-specific MAbs.
Remarkably, all of the MAbs, with the exception of 5H2.3B12.1C9, were
unable to recognize the mutants with carboxy terminus deletions (Fig.
4A to C; Table 2). Deletion of as few as 11 amino acids from the
carboxy terminus (C-11) of the N protein rendered all of the
conformation-dependent MAbs unresponsive. Given the fact that the only
MAb on the panel capable of recognizing the carboxy-terminal deletions
(5H2.3B12.1C9) was conformation independent, it is likely that the
region defined by domain V plays a critical role in maintaining overall
protein structure. Carboxy-terminal deletions must, therefore,
influence the structure of epitopes recognized by the
conformation-dependent N-specific MAbs under consideration. In previous
studies, conformation-dependent N-specific MAbs produced against a
European strain of PRRS virus failed to recognize N protein fragments
whose carboxy termini had been removed (22), which is
consistent with our observations. It is possible that the region
defined by domain V plays a role in N protein multimerization and
nucleocapsid assembly. Mutational analysis to dissect the C-terminal 11 amino acids for their contribution to MAb binding and the studies to
delineate multimerization of the N protein are presently in progress.
 |
ACKNOWLEDGMENTS |
This research was supported by the Ontario Ministry of
Agriculture, Food and Rural Affairs; the Ontario Research Enhancement Program of Agriculture and Agri-Food Canada; Ontario Pork; and USDA-NRI-CGP grant 9602270.
We thank J. Cho (Animal Disease Research Institute) for the
anti-PRRS virus swine polyclonal antiserum and the PA-8 strain of PRRS
virus; R. Magar for MAb 5H2.3B12.1C9; D. Deregt for MAbs 2G7, 1D2, 2D6,
and 7C10; and Eva Varady for her technical help.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, Ontario N1G 2W1, Canada. Phone: (519) 824-4120, ext. 4729. Fax: (519)
767-0809. E-mail: dyoo{at}ovcnet.uoguelph.ca.
 |
REFERENCES |
| 1.
|
Benfield, D. A.,
E. Nelson,
J. E. Collins,
L. Harris,
S. M. Goyal,
D. Robinson,
W. T. Christianson,
R. B. Morrison,
D. E. Gorcyca, and D. W. Chladek.
1992.
Characterization of swine infertility and respiratory syndrome (SIRS) virus (isolate ATCC VR-2332).
J. Vet. Diagn. Investig.
4:127-133[Abstract/Free Full Text].
|
| 2.
|
Cavanagh, D.
1997.
Nidovirales: a new order comprising Coronaviridae and Arteriviridae.
Arch. Virol.
142:629-633[Medline].
|
| 3.
|
Collins, J. E.,
D. A. Benfield,
W. T. Christianson,
J. E. Harris,
L. Hennings,
J. C. Shaw,
D. P. Goyal,
S. M. McCullough,
S. Morrison,
R. B. Joo,
H. S. Gorcyca, and D. W. Chladek.
1992.
Isolation of swine infertility and respiratory syndrome virus (isolate ATCC VR-2332) in North America and experimental reproduction of the disease in gnotobiotic pigs.
J. Vet. Diagn. Investig.
4:117-126[Abstract/Free Full Text].
|
| 4.
|
Conzelmann, K.,
N. Visser,
P. van Woensel, and H. Thiel.
1993.
Molecular characterization of porcine reproductive and respiratory syndrome virus, a member of the arterivirus group.
Virology
193:329[Medline].
|
| 5.
|
Denac, H.,
J. D. Tratschin, and M. A. Hofmann.
1997.
An indirect ELISA for the detection of antibodies against porcine reproductive and respiratory syndrome virus using recombinant nucleocapsid protein as antigen.
J. Virol. Methods
65:169-181[Medline].
|
| 5a.
| Deregt, D., and R. Magar. Personal communication.
|
| 6.
|
Drew, T. W.,
J. J. M. Meulenber,
J. J. Sands, and D. J. Paton.
1995.
Production, characterization and reactivity of monoclonal antibodies to the porcine reproductive and respiratory syndrome virus.
J. Gen. Virol.
76:1361-1369[Abstract/Free Full Text].
|
| 7.
|
Fuerst, T. R.,
E. G. Niles,
F. W. Studier, and B. Moss.
1986.
Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase.
Proc. Natl. Acad. Sci. USA
83:8122-8126[Abstract/Free Full Text].
|
| 8.
|
Garnier, J.,
D. J. Osguthorpe, and B. Robson.
1978.
Analysis of the accuracy and implications of simple methods for predicting the secondary structure of globular proteins.
J. Mol. Biol.
120:97-120[Medline].
|
| 9.
|
Kapur, V.,
M. R. Elam,
T. M. Pawlovich, and M. P. Murtaugh.
1996.
Genetic variation in porcine reproductive and respiratory syndrome virus isolates in the Midwestern United States.
J. Gen. Virol.
77:1271-1276[Abstract/Free Full Text].
|
| 10.
|
Kim, H. S.,
J. Kwang,
I. J. Yoon,
H. S. Joo, and M. L. Frey.
1993.
Enhanced replication of PRRS virus in a homogeneous subpopulation of MA-104 cell line.
Arch. Virol.
133:477-483[Medline].
|
| 11.
|
Magar, R.,
R. Larochelle,
S. Dea,
C. A. Gagnon,
E. A. Nelson,
J. Christopher-Hennings, and D. A. Benfield.
1995.
Antigenic comparison of Canadian and US isolates of porcine reproductive and respiratory syndrome virus using monoclonal antibodies to the nucleocapsid protein.
Can. J. Vet. Res.
59:232-234[Medline].
|
| 12.
|
Meng, X. J.,
P. S. Paul,
P. G. Halbur, and M. A. Lum.
1995.
Phylogenic analysis of the putative M (ORF 6) and N (ORF 7) genes of porcine reproductive and respiratory syndrome virus (PRRSV): implication for the existence of two genotypes of PRRSV in the U.S.A. and Europe.
Arch. Virol.
140:745-755[Medline].
|
| 13.
|
Meulenberg, J. J. M.,
A. den Besten,
E. P. De Kluyver,
R. J. M. Moormann,
V. M. M. Schaaper, and G. Wensvoort.
1995.
Characterization of proteins encoded by ORFs 2 to 7 of Lelystad virus.
Virology
206:155-163[Medline].
|
| 14.
|
Meulenberg, J. J. M.,
M. M. Hulst,
E. J. de Meijer,
P. J. L. M. Moonen,
A. den Besten,
E. P. De Kluyver,
G. Wensvoort, and R. J. M. Moormann.
1993.
Lelystad virus, the causative agent of porcine epidemic abortion and respiratory syndrome (PEARS), is related to LDV and EAV.
Virology
192:62-72[Medline].
|
| 15.
|
Nelson, E.,
J. Christopher-Hennings, and D. A. Benfield.
1994.
Serum immune responses to the proteins of PRRS virus.
J. Vet. Diagn. Investig.
6:410-415[Abstract/Free Full Text].
|
| 16.
|
Nelson, E.,
J. K. Nelson,
L. P. Couture,
M. L. Lau,
J. Christopher-Hennings,
C. C. L. Chase, and R. A. Hesse.
1997.
A single amino acid substitution allows for the differentiation of the Prime Pac PRRS® vaccine from field isolates of PRRSV, abstr. 202.
In
Proceedings of the 78th Conference of Research Workers in Animal Diseases, Chicago, Ill.
|
| 17.
|
Nelson, E. A.,
J. K. Christopher-Hennings,
T. Drew,
G. Wensvoort,
J. Collins, and D. A. Benfield.
1993.
Differentiation of U.S. and European isolates of porcine reproductive and respiratory syndrome virus by monoclonal antibodies.
J. Clin. Microbiol.
31:3184-3189[Abstract/Free Full Text].
|
| 18.
|
Nelson, E. A.,
J. K. Nelson,
J. Christopher-Hennings,
K.-J. Yoon,
R. Magar, and D. A. Benfield.
1996.
Reactivity of North American PRRSV isolates with a monoclonal antibody panel, p. 88.
In
Proceedings of the 14th International Pig Veterinary Society Congress, Bologna, Italy.
|
| 19.
|
Plagemann, P. G. W., and V. Moenning.
1992.
Lactate dehydrogenase elevating virus, equine arteritis virus, and simian hemorrhagic fever virus: a new group of positive strand RNA viruses.
Adv. Virus Res.
41:99-192[Medline].
|
| 20.
|
Plana-Duran, J.,
I. Climent,
J. Sarraseca,
A. Uriniza,
E. Cortes,
C. Vela, and J. I. Casal.
1997.
Baculovirus expression of proteins of porcine reproductive and respiratory syndrome virus strain Olot/91. Involvement of ORF3 and ORF5 proteins in protection.
Virus Genes
14:19-29[Medline].
|
| 21.
|
Raux, H.,
F. Iseni,
F. Lafay, and D. Blondel.
1997.
Mapping of monoclonal antibody epitopes of the rabies virus P protein.
J. Gen. Virol.
78:119-124[Abstract].
|
| 22.
|
Rodriguez, M. J.,
J. Sarraseca,
J. Garcia,
A. Sanz,
J. Plana-Duran, and J. I. Casal.
1997.
Epitope mapping of the nucleocapsid protein of European and North American isolates of porcine reproductive and respiratory syndrome virus.
J. Gen. Virol.
78:2269-2278[Abstract].
|
| 23.
|
Sambrook, J.,
E. F. Fritsch, and T. Maniatis.
1989.
Molecular cloning: a laboratory manual, 2nd ed.
Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
|
| 24.
|
van Alistine, W. G.,
G. W. Stevenson, and C. L. Kanitz.
1993.
Diagnosis of PRRS.
Swine Health Prod.
4:24-28.
|
| 25.
|
Wensvoort, G.,
E. P. de Kluyver,
E. A. Luitjze,
A. den Besten,
L. Harris,
J. E. Collins,
W. T. Christianson, and D. Chladek.
1992.
Antigenic comparison of Lelystad virus and swine infertility and respiratory syndrome (SIRS) virus.
J. Vet. Diagn. Investig.
4:134-138[Abstract/Free Full Text].
|
| 26.
|
Wensvoort, G.,
C. Tepstra,
J. M. A. Pol,
E. A. ter Laak,
M. Bloemraad,
E. P. de Kluyver,
C. Kragten,
L. van Buiten,
A. den Besten,
F. Wagenaar,
J. M. Broekhuijsen,
P. L. J. M. Moonen,
T. Zestra,
E. A. de Boer,
H. J. Tibben,
M. F. de Jong,
P. van Veld,
G. J. R. Groenland,
J. A. van Gennep,
M. T. Voets,
J. H. M. Verheijden, and J. Braamskamp.
1991.
Mystery swine disease in The Netherlands: the isolation of Lelystad virus.
Vet. Q.
13:121-130[Medline].
|
| 27.
|
Yoo, D.,
D. M. Parker,
J. Song,
G. J. Cox,
D. Deregt, and L. A. Babiuk.
1991.
Structural analysis of the conformational domains involved in the neutralization of bovine coronavirus using deletion mutants of the spike glycoprotein S1 subunit expressed by recombinant baculoviruses.
Virology
183:91-98[Medline].
|
Clinical and Diagnostic Laboratory Immunology, November 1998, p. 773-779, Vol. 5, No. 6
1071-412X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Okinaga, T., Yamagishi, T., Yoshii, M., Suzuki, T., Miyazaki, A., Takagi, M., Tsunemitsu, H.
(2009). Evaluation of unexpected positive results from a commercial ELISA for antibodies to PRRSV. Vet Rec.
164: 455-459
[Abstract]
[Full Text]
-
Choi, Y.-J., Yun, S.-I., Kang, S.-Y., Lee, Y.-M.
(2006). Identification of 5' and 3' cis-Acting Elements of the Porcine Reproductive and Respiratory Syndrome Virus: Acquisition of Novel 5' AU-Rich Sequences Restored Replication of a 5'-Proximal 7-Nucleotide Deletion Mutant. J. Virol.
80: 723-736
[Abstract]
[Full Text]
-
He, Y., Zhou, Y., Wu, H., Kou, Z., Liu, S., Jiang, S.
(2004). Mapping of Antigenic Sites on the Nucleocapsid Protein of the Severe Acute Respiratory Syndrome Coronavirus. J. Clin. Microbiol.
42: 5309-5314
[Abstract]
[Full Text]
-
Ferrin, N. H., Fang, Y., Johnson, C. R., Murtaugh, M. P., Polson, D. D., Torremorell, M., Gramer, M. L., Nelson, E. A.
(2004). Validation of a Blocking Enzyme-Linked Immunosorbent Assay for Detection of Antibodies against Porcine Reproductive and Respiratory Syndrome Virus. CVI
11: 503-514
[Abstract]
[Full Text]
-
Ropp, S. L., Wees, C. E. M., Fang, Y., Nelson, E. A., Rossow, K. D., Bien, M., Arndt, B., Preszler, S., Steen, P., Christopher-Hennings, J., Collins, J. E., Benfield, D. A., Faaberg, K. S.
(2004). Characterization of Emerging European-Like Porcine Reproductive and Respiratory Syndrome Virus Isolates in the United States. J. Virol.
78: 3684-3703
[Abstract]
[Full Text]
-
Wootton, S. K., Yoo, D.
(2003). Homo-Oligomerization of the Porcine Reproductive and Respiratory Syndrome Virus Nucleocapsid Protein and the Role of Disulfide Linkages. J. Virol.
77: 4546-4557
[Abstract]
[Full Text]
-
Wootton, S. K., Rowland, R. R. R., Yoo, D.
(2002). Phosphorylation of the Porcine Reproductive and Respiratory Syndrome Virus Nucleocapsid Protein. J. Virol.
76: 10569-10576
[Abstract]
[Full Text]
-
Stadejek, T., Stankevicius, A., Storgaard, T., Oleksiewicz, M. B., Belak, S., Drew, T. W., Pejsak, Z.
(2002). Identification of radically different variants of porcine reproductive and respiratory syndrome virus in Eastern Europe: towards a common ancestor for European and American viruses. J. Gen. Virol.
83: 1861-1873
[Abstract]
[Full Text]
-
Oleksiewicz, M. B., Botner, A., Normann, P.
(2002). Porcine B-cells recognize epitopes that are conserved between the structural proteins of American- and European-type porcine reproductive and respiratory syndrome virus. J. Gen. Virol.
83: 1407-1418
[Abstract]
[Full Text]
-
Wootton, S., Koljesar, G., Yang, L., Yoon, K.-J., Yoo, D.
(2001). Antigenic Importance of the Carboxy-Terminal Beta-Strand of the Porcine Reproductive and Respiratory Syndrome Virus Nucleocapsid Protein. CVI
8: 598-603
[Abstract]
[Full Text]